These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Low-dose busulphan conditioning and neonatal stem cell transplantation preserves vision and restores hematopoiesis in severe murine osteopetrosis. Askmyr M; Holmberg J; Flores C; Ehinger M; Hjalt T; Richter J Exp Hematol; 2009 Feb; 37(2):302-8. PubMed ID: 19100677 [TBL] [Abstract][Full Text] [Related]
44. The nature of tolerance in adult recipient mice made tolerant of alloantigens with supralethal irradiation followed by syngeneic bone marrow cell transplantation plus injection of F1 spleen cells. Tomita Y; Himeno K; Mayumi H; Tokuda N; Nomoto K Transplantation; 1989 Jun; 47(6):1021-9. PubMed ID: 2660340 [TBL] [Abstract][Full Text] [Related]
45. The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice. Mayumi H; Good RA Transplant Proc; 1988 Feb; 20(1 Suppl 1):139-41. PubMed ID: 2894728 [No Abstract] [Full Text] [Related]
47. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Frattini A; Blair HC; Sacco MG; Cerisoli F; Faggioli F; Catò EM; Pangrazio A; Musio A; Rucci F; Sobacchi C; Sharrow AC; Kalla SE; Bruzzone MG; Colombo R; Magli MC; Vezzoni P; Villa A Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14629-34. PubMed ID: 16195375 [TBL] [Abstract][Full Text] [Related]
48. Imaging of malignant infantile osteopetrosis before and after bone marrow transplantation. Cheow HK; Steward CG; Grier DJ Pediatr Radiol; 2001 Dec; 31(12):869-75. PubMed ID: 11727023 [TBL] [Abstract][Full Text] [Related]
49. [Cure of osteopetrosis by injection of allogenic bone marrow into "op" rats treated with cyclosporin A]. Moutier R; Toyama K; Lamendin H C R Acad Sci III; 1985; 301(10):483-5. PubMed ID: 3937567 [TBL] [Abstract][Full Text] [Related]
50. [Stem cell transplantation--more than bone marrow transplantation]. Egeland T; Thorsby E Nord Med; 1995; 110(12):307-9. PubMed ID: 8524629 [TBL] [Abstract][Full Text] [Related]
51. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide is feasible in bone marrow transplantation for osteopetrosis. Naithani R Pediatr Transplant; 2015 Nov; 19(7):801-2. PubMed ID: 26179773 [No Abstract] [Full Text] [Related]
57. Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection. Zhang Y; Yasumizu R; Sugiura K; Hashimoto F; Amoh Y; Lian Z; Cherry ; Nishio N; Ikehara S Eur J Immunol; 1994 Jul; 24(7):1558-65. PubMed ID: 7913037 [TBL] [Abstract][Full Text] [Related]
58. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061 [TBL] [Abstract][Full Text] [Related]
59. Haematopoietic stem cells transduced with a single donor class I major histocompatibility complex gene can induce operational tolerance to fully allogeneic cardiac allografts. Wong W; Fry J; Hyde K; Stranford S; Morris PJ; Wood KJ Transplant Proc; 1999; 31(1-2):886. PubMed ID: 10083388 [No Abstract] [Full Text] [Related]
60. Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products. Or R; Aker M; Shapira MY; Resnick I; Bitan M; Samuel S; Slavin S Springer Semin Immunopathol; 2004 Nov; 26(1-2):133-42. PubMed ID: 15549305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]